Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Capricor Therapeutics (CAPR) EBIT (2016 - 2025)

Historic EBIT for Capricor Therapeutics (CAPR) over the last 17 years, with Q3 2025 value amounting to -$26.3 million.

  • Capricor Therapeutics' EBIT fell 10203.14% to -$26.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$74.7 million, marking a year-over-year decrease of 10667.89%. This contributed to the annual value of -$42.6 million for FY2024, which is 7678.0% down from last year.
  • Per Capricor Therapeutics' latest filing, its EBIT stood at -$26.3 million for Q3 2025, which was down 10203.14% from -$27.7 million recorded in Q2 2025.
  • Over the past 5 years, Capricor Therapeutics' EBIT peaked at -$1.3 million during Q4 2023, and registered a low of -$27.7 million during Q2 2025.
  • Its 5-year average for EBIT is -$9.8 million, with a median of -$7.7 million in 2023.
  • In the last 5 years, Capricor Therapeutics' EBIT surged by 8411.56% in 2023 and then tumbled by 50078.74% in 2024.
  • Quarter analysis of 5 years shows Capricor Therapeutics' EBIT stood at -$6.4 million in 2021, then dropped by 26.44% to -$8.1 million in 2022, then skyrocketed by 84.12% to -$1.3 million in 2023, then crashed by 500.79% to -$7.7 million in 2024, then plummeted by 241.45% to -$26.3 million in 2025.
  • Its last three reported values are -$26.3 million in Q3 2025, -$27.7 million for Q2 2025, and -$7.7 million during Q4 2024.